Showing 6531-6540 of 8876 results for "".
- ADCS Acquires Additional Clinicshttps://practicaldermatology.com/news/20121008-adcs_acquires_additional_clinics/2459714/Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of the Center For Dermatology & Skin Surgery, Inc. (CDSS) and its seven clinics in West Central Florida. Headquartered in Tampa, FL, CDSS was founded by Steve
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- ISHRS Kicks Off 20th Anniversaryhttps://practicaldermatology.com/news/20121003-ishrs_kicks_off_20th_anniversary/2459716/The International Society of Hair Restoration Surgery kicks off its 20th Anniversary this month. The ISHRS Annual Scientific Meeting is October 17-20 at Atlantis, Paradise Island, the Bahamas. The society is highlighting follicular units in hair res
- Stiefel/GSK Receives FDA Approval of Sorilux Foam, 0.005%https://practicaldermatology.com/news/20121002-stiefel_receives_fda_approval_of_sorilux_foam_0005/2459719/The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005% from Stiefel/GSK. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psor
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Aesthetics Course Offers Cosmetic Practitioners Practical Business Advicehttps://practicaldermatology.com/news/20121002-aesthetics_course_offers_cosmetic_practitioners_practical_business_advice/2459724/Registration is now open for “Mastering the Business of Aesthetics” (MBA), a one-day course that teaches vital lessons regarding the financial components of cosmetic practice. The course will take place in Beverly Hills, CA on October 27th and cover topics such as optimizing laser business, increasi
- NeoStrata Launches SKIN ACTIVE Perfecting Peelhttps://practicaldermatology.com/news/20120918-neostrata_launches_skin_active_perfecting_peel/2459736/NeoStrata Company, Inc., the creators of the original glycolic acid peel, introduced the Perfecting Peel to SKIN ACTIVE, its line of antiaging skincare. SKIN ACTIVE Perfecting Peel is formulated with a 20% alpha hydroxy acid blend of 10% citric
- Colorescience's Diane Ranger to Receive Innovators in Dermatology Award at CSF 2012https://practicaldermatology.com/news/20120917-coloresciences_diane_ranger_to_receive_innovators_in_dermatology_award_at_csf_2012/2459738/Diane Ranger, Founder and President of Colorescience Mineral Makeup, and acknowledged inventor of mineral makeup, will receive the "Innovators in Dermatology Award" at Cosmetic Surgery F
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA